JPS6150917A - Remedying composition for alcoholic hepatopathy - Google Patents
Remedying composition for alcoholic hepatopathyInfo
- Publication number
- JPS6150917A JPS6150917A JP59172793A JP17279384A JPS6150917A JP S6150917 A JPS6150917 A JP S6150917A JP 59172793 A JP59172793 A JP 59172793A JP 17279384 A JP17279384 A JP 17279384A JP S6150917 A JPS6150917 A JP S6150917A
- Authority
- JP
- Japan
- Prior art keywords
- ornithine
- alanine
- composition
- food
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
Abstract
Description
【発明の詳細な説明】
［産業上の利用分野］
本発明は、急性アルコール中毒等のアルコール性肝障害
を軽減する抗アルコール性肝障害作用を有する食品又は
医薬組成物に関する。DETAILED DESCRIPTION OF THE INVENTION [Industrial Application Field] The present invention relates to a food or pharmaceutical composition having an anti-alcoholic liver damage effect that alleviates alcoholic liver damage such as acute alcohol poisoning.
［従来の技術］
アルコール性肝ＶＪ害は、軽度の意識障害から、昏睡、
昏迷状態、更には急性アルコール中毒による致死までの
種々の障害所見を呈する。[Prior art] Alcoholic liver VJ damage can range from mild consciousness disturbance to coma and
The patient exhibits various symptoms ranging from stupor to death due to acute alcohol intoxication.
このようなアルコール性肝障害を軽減し、若しくは、治
免する目的で、プロトポルフィリン系製剤、グルクロン
酸製剤等並びに、アルギニン塩酸塩等のアミノ酸製剤な
どが従来用いられてきた。For the purpose of alleviating or curing such alcoholic liver damage, protoporphyrin preparations, glucuronic acid preparations, and amino acid preparations such as arginine hydrochloride have conventionally been used.
アミノ酸としては、この他、バリン、０イシン、イソ０
イシン等の分枝鎖アミノ酸、待にバリンの投与が肝性昏
Ｉ！患者の容態の急激な回復に有効であるとの知見（特
公昭５７−２９４４６）や、オルニチンが肝性昏睡にお
いて肝臓におけるアンモニアの解ｍ１ｎ泄＆’ｌ ｆｆ
：を改菅する等の知見が存在する。Other amino acids include valine, 0isine, iso0
Administration of branched chain amino acids such as isin, and especially valine causes hepatic coma! The knowledge that ornithine is effective for rapid recovery of the patient's condition (Japanese Patent Publication No. 57-29446), and that ornithine is effective for the dissolution of ammonia in the liver &'l ff in hepatic coma.
There is knowledge that:
また、オルニチンについては、アデノシン三燐酸との塩
が上記アンモニアの解毒***にすぐれた効果を発揮する
ことも報告されている（特公昭４ｌ−９３１６）。It has also been reported that a salt of ornithine with adenosine triphosphate exhibits an excellent effect on the detoxification and excretion of ammonia (Japanese Patent Publication No. 41-9316).
〔発明が解決しようとするＩＯ！題点］本発明は、医薬
の投与にょる冶逐的回復手段に限定されがちであったア
ルコール性肝障害のｌＩｌ減乃至は回復を、冶シ効果の
みならず、予防にもすぐれた効果を介在する物質を食品
等の自然な形態で摂取せしむることにより、安全かつ効
果的にフルール性肝障害の防止並びに冶癒を行うことを
目的とする。[IO that the invention tries to solve! [Problem] The present invention provides not only a therapeutic effect but also an excellent preventive effect on the reduction or recovery of alcoholic liver damage, which has tended to be limited to remedial measures such as the administration of pharmaceuticals. The purpose is to safely and effectively prevent and cure fleur-induced liver damage by ingesting intervening substances in natural forms such as foods.
［問題点を解決するための手段］
本発明者らは、アルコール性肝障害における肝ミトコン
ドリア障害による代謝変動を考究する中で、絶食後のマ
ウスを用いた急性エタノール中応実験にて、救命効果を
有する物質を見い出した。[Means for Solving the Problems] While investigating the metabolic changes caused by liver mitochondrial damage in alcoholic liver injury, the present inventors conducted an acute ethanol reaction experiment using fasted mice, and found that the life-saving effect was We have discovered a substance that has
即ち、アラニン等数種のアミノ酸に救命効果が見られ、
更にアラニンとオルニチンとを同時投与した場合に著し
く強い救命効果、肝組織障害軽減効果、意識障害軽減効
果が認められた。一方、７ラニンやオルニチン単独ＩＱ
与群では、それらの効果は認められなかった。In other words, several types of amino acids such as alanine have been shown to have life-saving effects.
Furthermore, when alanine and ornithine were administered simultaneously, a significantly stronger life-saving effect, an effect of reducing liver tissue damage, and an effect of reducing consciousness disturbance were observed. On the other hand, IQ of 7ranine and ornithine alone
In the given group, these effects were not observed.
従って、本発明において、必須の有効成分は、アラニン
及びオルニチンであり、両者を併用すること並びに両者
の併用比率が本発明における必須の（１′４成要件を成
す。Therefore, in the present invention, the essential active ingredients are alanine and ornithine, and the combination of both and their combined ratio constitute the essential (1'4 component) requirements of the present invention.
［実験例］ マウスの急性エタノール中毒実験実験法：
ＪＣｌ ： ｆｃＲ系の生（す約６週間のマウスを用い
、約２０時間紙食（水分可）後に第１表及び第２表に示
す検定物質（０，９％Ｎａ Ｃ１液中の０．１又は０．
１２５Ｍ、Ｉ）Ｈ７，４）をＩｔ！２腔内に注射し、対
照には、同この０．９％ＮａＣ１液を腹腔内に注射した
。その約４０分後に、０．９％ＮａＣＪＬ液中の１９％
Ｗ／Ｖ［７）工９／−ル１７０ ｍｍｏｌ／に１体重を
腹腔内に注射し、その後５日間の生存率を調べた。[Experiment example] Experimental method for acute ethanol poisoning in mice:
JCl: Using live mice of the fcR strain (approximately 6 weeks old), test substances shown in Tables 1 and 2 (0.1% in 0.9% NaCl solution or 0.
125M, I) H7, 4) It! For controls, the same 0.9% NaCl solution was injected intraperitoneally. Approximately 40 minutes later, 19% in 0.9% NaCJL solution
One body weight was intraperitoneally injected into 170 mmol/W/V [7) drug, and the survival rate was then examined for 5 days.
結果：第１表及び第２表に示す如く、４０匹の対照酊で
は、生存率は３５％であった。各種アミノ酸、グルコー
スや各種有は酸の救命効果＠調べた。その結果、アラニ
ン、スレオニン、ロイシンやインロイシンなどのアミノ
酸にやや強い救命効果が見られた。アラニン単独では、
生存＄、は６７％に増加したが、アラニンに受面のオル
ニチンを加え、ＩＱ与することによって、生存率は１０
０％と著しく増加した。オルニチン 単独投与では、生
存率の増加は見られなかった。アラニン＋オルニヂン投
与（ＡＯ投与）群では、体重の増加も、対照／ｌＴに比
べ大きかった。対照詳の肝祖宸像は、Ｈ−Ｅ染色で、中
心静脈周囲に、変性、壮大した肝細胞が著明に見られた
が、ＡＯ投与群では、それらの肝組ｆＪ ｍ害所見が軽
減されていた。Results: As shown in Tables 1 and 2, in the 40 control mice, the survival rate was 35%. Various amino acids, glucose, and various compounds were investigated for the life-saving effects of acids. The results showed that amino acids such as alanine, threonine, leucine, and inleucine had a somewhat stronger life-saving effect. Alanine alone,
The survival rate increased to 67%, but by adding ornithine to alanine and giving IQ, the survival rate increased to 10%.
This markedly increased to 0%. No increase in survival rate was observed when ornithine was administered alone. In the alanine + ornidine administration (AO administration) group, the increase in body weight was also greater than in the control/IT group. The detailed liver image of the control group was stained with H-E, and degenerated and enlarged hepatocytes were clearly seen around the central vein, but in the AO administration group, these liver tissue damage findings were reduced. It had been.
アラニンとオルニチンとの併用比率は、例えば、アラニ
ンの投与崖に応じ、その最適比率が異なり、効果も変化
するが、概して、アラニンとオルニチンとの併用比率は
、モル１１！度比でアラニンに対しオルニチンが１／
１０００倍モル以上である。アラニンに対するオルニチ
ンのａの上限はないが、アラニンの投与はを一定にした
場合、オルニチンの併用投与社が増大しても、効果の比
例的増大はみられず、逆に官能面、経済面でマイナスの
効果を生ずる。従って、主として、官能及び経済的理由
により、オルニチンのアラニンに対する併用比率の上限
は１０倍モルである。一方、アラニンに対するオルニチ
ンの併用比率の下限は、少■のオルニチンの併用でも効
果を秦するが、１／１０００倍モルを下回ると、はとん
どその効果は期待できなくなる。従って、アラニンとオ
ルニチンの併用比率は、モル温度比で、好ましくは１
：０．００１〜１０であり、至適には１ 二Ｏ，０５〜
０．５である。For example, the optimum ratio of the combined use of alanine and ornithine varies depending on the dosage level of alanine, and the effect also changes, but in general, the combined use ratio of alanine and ornithine is 11 moles! The ratio of ornithine to alanine is 1/1
It is 1000 times more molar or more. There is no upper limit for the a of ornithine relative to alanine, but when the amount of alanine administered is kept constant, even if the number of co-administered ornithine increases, there is no proportional increase in the effect; produce negative effects. Therefore, mainly due to sensory and economical reasons, the upper limit of the combined ratio of ornithine to alanine is 10 times molar. On the other hand, as for the lower limit of the combined ratio of ornithine to alanine, even if a small amount of ornithine is used in combination, the effect will be diminished, but if it is less than 1/1000 times mole, the effect will hardly be expected. Therefore, the combined ratio of alanine and ornithine is preferably 1 in terms of molar temperature ratio.
:0.001~10, optimally 12O,05~
It is 0.5.
アラニン及びオルニチンは、生体内でアラニン又はオル
ニチンとして有効に作用ずれば、塩或いはその他の＝１
ｓ体であっても使用できる。好ましい組合けの０体例
としては、し−アラニンとＬ−オルニチン、ＯＬ−アラ
ニンとし一オルニチン、し−アラニンとＬ−オルニチン
塩酸塩、ＯＬ−アラニンとＬ−オルニチン塩酸塩等が挙
げられる。If alanine and ornithine act effectively as alanine or ornithine in vivo, salt or other =1
Even the s-form can be used. Examples of preferred combinations include -alanine and L-ornithine, OL-alanine and mono-ornithine, -alanine and L-ornithine hydrochloride, and OL-alanine and L-ornithine hydrochloride.
本発明の組成物は、医薬又は念品の形態で提供できる。The composition of the present invention can be provided in the form of a medicament or a medicinal product.
医薬は、経口的に又は非経口的に適用され得る。The medicament may be applied orally or parenterally.
本発明の医薬が提供される形ｒ＆としては、経口投与用
には、例えば、散剤、顆粒、錠剤、砧衣錠、カプセル、
液剤等、非経口投与用には例えば、懸濁液、液剤、乳剤
、アンプル及び注射液等が挙げられ、或いは、これらを
組合せた形態でも提供できる。組合Ｌ’ｌ！する希釈剤
としては、固体、半固体及び液体のいずれでもよく、例
えば、水、ゼラチン、糖類、澱粉類、脂肪酸、その塩、
アルコール、油脂、タルク、生理介塩水等又はこれらの
２種以上の組合ぜが？トげられる。本発明医薬における
アラニン、オルニチン及び／又はそれらの塩の総重巳が
占める比率は、一般に０．０１〜１００重足％である。For oral administration, the form in which the medicament of the present invention is provided includes, for example, powders, granules, tablets, coated tablets, capsules,
Liquid preparations for parenteral administration include, for example, suspensions, liquid preparations, emulsions, ampoules, and injection solutions, or a combination of these may also be provided. Union L'l! The diluent may be solid, semi-solid or liquid, such as water, gelatin, sugars, starches, fatty acids, salts thereof,
Alcohol, oil, fat, talc, physiological saline, etc., or a combination of two or more of these? I can get hit. The total weight ratio of alanine, ornithine and/or their salts in the pharmaceutical of the present invention is generally 0.01 to 100 weight%.
一方、本発明組成物は、食品として極めて有効に提供し
くｑる。好ましい食品の形態としては、アルコール類と
同時に、或いは相前後して摂取される食品であり、具体
的には、くん甘い、サキイカ、塩カラ、カラスミ、イク
ラ、明太子、タラ子、キャビア、フォアグラ、腐乳、豆
腐、チーズ、ポテトチップ、米菓、豆菓子その他のいわ
ゆる酒の肴、つまみ類として常用されるｔ＆蛋白質系食
品、高油脂系食品、高油脂系食品の類、或いは、焼肉の
タレ、刺身醤油、湯豆腐・冷奴のタレ、ドレッシング・
マヨネーズ等のソース類、ラー油、食酢、食卓塩等の調
味料、更に、日本酒、ビール、焼酎、ワイン、ウィスキ
ー、ブランディー、老酒、ジン、ラム、カンバリ、ヴエ
ルモット、各種のカクテル類等のアルコール飲料・スポ
ーツドリンク、トマトジュースその他のジュース、コー
ラ等のソフトドリンク類などが挙げられる。On the other hand, the composition of the present invention can be provided extremely effectively as a food. Preferred food forms include foods that are consumed at the same time as or in succession to alcoholic beverages, such as sweet fish, saki squid, salted roe, mullet, salmon roe, mentaiko, cod roe, caviar, foie gras, Rotten milk, tofu, cheese, potato chips, rice crackers, bean snacks, and other so-called alcoholic accompaniments, T& protein foods commonly used as snacks, high-fat foods, high-fat foods, or yakiniku sauce, Sashimi soy sauce, boiled tofu/cold tofu sauce, dressing
Sauces such as mayonnaise, seasonings such as chili oil, vinegar, and table salt, and alcoholic beverages such as sake, beer, shochu, wine, whiskey, brandy, aged sake, gin, rum, kanbari, vellmot, and various cocktails. - Examples include sports drinks, tomato juice and other juices, and soft drinks such as cola.
本発明の食品におけるアラニン、オルニチン乃び／又ｔ
よそれらの塩の総重沿の占める比率は、一般に０．０１
〜１０％である。官能面で、本発明のアミノ酸の高濃度
での使用が好ましくない場合、例えば、比較的ｇ融点の
油脂、蛋白、Ｘ！粉等でカプセル化して用いる、或いは
、マスキング剤を併用する等の方法の採用が好ましい。Alanine, ornithine and/or t in the food of the present invention
The ratio of the total weight of these salts is generally 0.01
~10%. In cases where it is not desirable to use the amino acids of the present invention at high concentrations from a functional point of view, for example, fats and oils with a relatively high melting point, proteins, X! It is preferable to use methods such as encapsulating the material with powder or the like, or using a masking agent in combination.
尚、本発明組成物は、アラニン及びオルニチンを必須の
有効成分として含有するが、その他のアミノ酸類の共存
は、本発明の目的を逸脱しない限り、可能なことはいう
までもない。Although the composition of the present invention contains alanine and ornithine as essential active ingredients, it goes without saying that other amino acids may be present in the composition as long as they do not depart from the purpose of the present invention.
［ｒＦ−用Ｊ
本発明のアラニン及びオルニチン組成物投与により急性
エタノール中庭貫設にみられる如く、強い救命効果が得
られ、エタノール投与に・よる肝組１１障害所見の軽減
もみられる。エタノール投与によるＱ識障害は、本発明
組成物投与によって軽減され、本発明組成物投与による
血中エタノール除去能の亢進ちみられる。また、本発明
組成物投与群にエタノール投与後の有意の１１ｈ粘の上
昇があり、このようなＭＦｒ生の亢進は、尿素サイクル
を促進するとされるオルニチン投与が、エタノール投与
とともに必要であり、尿素サイクル糖新生とエタノール
などの代謝の関連において、アラニンとオルニチンとの
併用投与による救命効果が生じたものと考えられる。[J for rF- By administering the alanine and ornithine composition of the present invention, a strong life-saving effect can be obtained as seen in acute ethanol penetration, and a reduction in liver tissue 11 damage caused by ethanol administration is also observed. The Q perception disorder caused by the administration of ethanol is alleviated by the administration of the composition of the present invention, and the blood ethanol removal ability is enhanced by the administration of the composition of the present invention. In addition, there was a significant increase in 11-h viscosity after ethanol administration in the group administered with the composition of the present invention, and this enhancement of MFr production suggests that ornithine administration, which is said to promote the urea cycle, is necessary together with ethanol administration; It is thought that the combined administration of alanine and ornithine had a life-saving effect in the relationship between cyclic gluconeogenesis and metabolism of ethanol and other substances.
次に、実施例により、本発明を更に説明する。Next, the present invention will be further explained by examples.
実施例１
第４表に示ず組成で、アラニンとオルニチンを併用投与
し、急性エタノール中６１症に対する本発明組成物の救
命効果を調べた。（使用マウス、実験法は、実験例と同
様）
結果は第４表に示す如く、アラニンとオルニチンの併用
投与により、著しい救命効果がみられ、特に、アラニン
、オルニチンのモルＦＱ度比が１：０．２５で１００％
の生存率であった。Example 1 Alanine and ornithine were administered together in a composition not shown in Table 4, and the life-saving effect of the composition of the present invention on acute ethanol-induced 61 symptoms was investigated. (The mice used and the experimental method were the same as in the experimental example.) As shown in Table 4, the combined administration of alanine and ornithine had a remarkable life-saving effect, especially when the molar FQ ratio of alanine and ornithine was 1: 100% at 0.25
The survival rate was
実施例２
エタノールを１００ ｍｎ＋ｏｆ／ Ｋｇ体重と実験例
に比べ、その投与徂をやや減少させた他は、実験例と同
じ条件で、エタノール投与による意識障害と血糖及び血
中エタノール値における、アミノ酸投与による影響を調
べた。結果は、エタノール投与後のマウスの昏睡や昏迷
状態を観察すると、ＡＯ組成物投与群では、意謀障害の
程度が、著しく軽減されていたが、アラニンやオルニチ
ン単独投与群では、その効果は見られなかった。この実
験と同じ条件で、眼底から採血し、血糖と血中エタノー
ルけの変シＪを調べた。対照群に比べ、ＡＯ組成物投与
群では、血中エタノール除去速度の促進が見られたが、
アラニンやオルニチン単独投与群では、その効果は見ら
れなかった。また、ＡＯ組成物投与群では、エタノール
投与後に徐々に血ｔＪ！Ｊ値が増加し、他群より有意に
高い血糖値が示された。Example 2 Amino acid administration was performed under the same conditions as in the experimental example, except that ethanol was administered at 100 mn+/kg body weight and the dose range was slightly reduced compared to the experimental example. We investigated the influence of The results showed that when observing the coma or stupor state of mice after ethanol administration, the degree of intentionality disorder was significantly reduced in the group administered with the AO composition, but no such effect was observed in the group administered with alanine or ornithine alone. I couldn't. Under the same conditions as in this experiment, blood was collected from the fundus of the eye and changes in blood sugar and blood ethanol were examined. Compared to the control group, the blood ethanol removal rate was accelerated in the AO composition administration group;
No such effect was observed in the groups administered with alanine or ornithine alone. In addition, in the AO composition administration group, blood tJ gradually increased after ethanol administration. The J value increased, and blood sugar levels were significantly higher than those in other groups.
実施例３
市販スポーツドリンクに、常法により固型脂でマイクロ
カプセル化した本発明の組成物をアラニン５９／ｄｉ、
オルニチン１．５！７／ｄｉとなるように添加し、アラ
ニン及びオルニチン入りスポーツドリンクを調製した。Example 3 The composition of the present invention microencapsulated with solid fat in a commercially available sports drink was added to alanine 59/di,
Ornithine was added at a concentration of 1.5!7/di to prepare a sports drink containing alanine and ornithine.
ＩＥＩられたスポーツドリンクを、実施例２と同一条件
でマウスの腹腔内に注！ＩＮ １．、、、その他の条ｒ
トも実施例２と同一にして、エタノール投与に５ける意
識Ｐ５害と血糖及び血中エタノール値における。Inject the IEI sports drink into the abdominal cavity of mice under the same conditions as in Example 2! IN 1. , , other provisions
The results were also the same as in Example 2, and the effects of ethanol administration on P5 consciousness, blood sugar, and blood ethanol levels were evaluated.
アミノ酸１９与による影響を調べたところ、本発明の組
成フ勿Ｃ有スポーツドリンク投与群は、対照投与群に比
べ、意識障害の程度が著しく軽減されていた。When the effects of amino acid 19 administration were investigated, the degree of disturbance of consciousness was significantly reduced in the group administered with the sports drink containing the composition of the present invention compared to the control group.
Claims (1)
濃度比で含有することを特徴とする抗アルコール性肝障
害組成物。[Scope of Claims] An anti-alcoholic liver damage composition comprising alanine and/or a salt thereof and ornithine and/or a salt thereof in a molar concentration ratio of 1:0.001 or more.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP59172793A JPS6150917A (en) | 1984-08-20 | 1984-08-20 | Remedying composition for alcoholic hepatopathy |
| US06/762,281 US4596825A (en) | 1984-08-20 | 1985-08-05 | Method of treating liver disturbances resulting from alcohol consumption and a composition therefor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP59172793A JPS6150917A (en) | 1984-08-20 | 1984-08-20 | Remedying composition for alcoholic hepatopathy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP4281140A Division JPH075459B2 (en) | 1992-09-28 | 1992-09-28 | Anti-alcoholic liver injury composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPS6150917A true JPS6150917A (en) | 1986-03-13 |
Family
ID=15948459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP59172793A Expired - Lifetime JPS6150917A (en) | 1984-08-20 | 1984-08-20 | Remedying composition for alcoholic hepatopathy |
Country Status (2)
| Country | Link |
|---|---|
| US (1) | US4596825A (en) |
| JP (1) | JPS6150917A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61134313A (en) * | 1984-12-03 | 1986-06-21 | Suntory Ltd | Agent for suppressing toxicity of aldehyde |
| JPH05213746A (en) * | 1992-09-28 | 1993-08-24 | Ajinomoto Co Inc | Anti-alcoholic hepatopathy composition |
| WO2010140716A1 (en) * | 2009-05-30 | 2010-12-09 | 주식회사 엠에이치투 바이오케미칼 | Composition and alcoholic beverage for relieving hangovers and including ornithine or an ornithine salt |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI82483C (en) * | 1986-12-03 | 1991-03-11 | Inst Biolog Morya Dalnevostoch | FOERFARANDE FOER FRAMSTAELLNING AV EN ALKOHOLDRYCK. |
| US4808574A (en) * | 1986-12-03 | 1989-02-28 | Nauchno-Issledovatelsky Institut Sadovodstva | Composition inhibiting pathological addiction to alcohol |
| EP0336960A4 (en) * | 1987-10-19 | 1990-02-20 | Joseph A Haklitch | Detoxifying food supplement. |
| JPH01216924A (en) * | 1988-02-24 | 1989-08-30 | Ajinomoto Co Inc | Therapeutic agent for hepatic disorder |
| WO1996008979A1 (en) | 1994-09-22 | 1996-03-28 | Quadrant Holdings Cambridge Limited | Compositions for use in rehydration and nutrition during athletic exercise and methods of making same |
| AU2003261825A1 (en) * | 2002-08-30 | 2004-03-19 | Ajinomoto Co., Inc. | Therapeutic agent for hepatic disease |
| US20050100636A1 (en) * | 2003-11-10 | 2005-05-12 | Megan Botteri | [A Low-Calorie Sports Drink For Physically Active Women That is Fortified with Iron, Calcium and Essential Vitamins for Use in Rehydration and Replacing Electrolytes Lost During Periods of Physical Activity] |
| CN101111242A (en) * | 2005-01-31 | 2008-01-23 | 协和发酵工业株式会社 | Tablets containing ornithine hydrochloride |
| EA201800027A1 (en) | 2015-06-19 | 2018-06-29 | Харша Чигурупати | COMPOSITION OF SYNERGETIC DRINKS |
| EP3257513A1 (en) | 2016-06-18 | 2017-12-20 | Chigurupati, Harsha | Composition to reduce dna and hepatic damage and to enhance repair thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5627493A (en) * | 1979-08-14 | 1981-03-17 | Nippon Electric Co | Method and device for identifying bill |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3950529A (en) * | 1975-02-03 | 1976-04-13 | Massachusetts General Hospital | Amino acid formulations for patients with liver disease and method of using same |
| JPS5536457A (en) * | 1978-09-08 | 1980-03-14 | Ajinomoto Co Inc | Amino acid infusion |
-
1984
- 1984-08-20 JP JP59172793A patent/JPS6150917A/en not_active Expired - Lifetime
-
1985
- 1985-08-05 US US06/762,281 patent/US4596825A/en not_active Expired - Lifetime
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5627493A (en) * | 1979-08-14 | 1981-03-17 | Nippon Electric Co | Method and device for identifying bill |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61134313A (en) * | 1984-12-03 | 1986-06-21 | Suntory Ltd | Agent for suppressing toxicity of aldehyde |
| JPH05213746A (en) * | 1992-09-28 | 1993-08-24 | Ajinomoto Co Inc | Anti-alcoholic hepatopathy composition |
| WO2010140716A1 (en) * | 2009-05-30 | 2010-12-09 | 주식회사 엠에이치투 바이오케미칼 | Composition and alcoholic beverage for relieving hangovers and including ornithine or an ornithine salt |
Also Published As
| Publication number | Publication date |
|---|---|
| US4596825A (en) | 1986-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4739161B2 (en) | Endurance improver | |
| EP1089726B1 (en) | Composition comprising ss-hydroxy-ss-methylbutyric acid and at least one amino acid | |
| US7932288B2 (en) | Composition for relieving subjective symptoms of fatigue | |
| JPS6150917A (en) | Remedying composition for alcoholic hepatopathy | |
| WO2013035479A1 (en) | Composition for improving in vivo metabolism parameter | |
| JP6193229B2 (en) | Preventive or ameliorating agent for vascular endothelial function decline | |
| EP1993522A2 (en) | Resveratrol and/or grape leaf extract as i.a. endurance improver, anti-aging agent, muscle strength improver | |
| JP5046174B2 (en) | Arginine-containing composition for increasing blood flow | |
| JP5128828B2 (en) | Anti-inflammatory and antioxidant | |
| JP2004262878A (en) | Composition and food or beverage each having bloodstream improving action | |
| EP1714650B1 (en) | Arginine-containing compositions for increasing blood flow | |
| JP2015535241A (en) | Preventing or improving brain function | |
| JP2006193435A (en) | Fatigue-improving agent | |
| JP5294149B2 (en) | Glutamine-containing composition for increasing blood flow | |
| JPH0420409B2 (en) | ||
| JP2022019972A (en) | Composition for mitigating fatigue feeling and improving stiffness | |
| JPH05213746A (en) | Anti-alcoholic hepatopathy composition | |
| WO1999016433A1 (en) | Remedy for hepatopathy | |
| AU692903B2 (en) | Hemopoietic function-stimulating agent | |
| JP3712539B2 (en) | Liver disease treatment | |
| JP2012162566A (en) | Anti-inflammatory agent and antioxidant | |
| KR102621956B1 (en) | Composition having antihypertensive effect comprising chp (cyclo-his pro) | |
| JPH0881372A (en) | Preventive/therapeutic agent for medical symptom due to decrease in erytherocyte number | |
| JP6170166B2 (en) | Preventing or improving brain function | |
| JPWO2016072496A1 (en) | Alcohol metabolism promoter |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EXPY | Cancellation because of completion of term |